Replies to post #110987 on Cytodyn Inc (CYDY)

[Borel Fields]

Indeed - if the SOFA (organ failure) secondary endpoint, including coagulation issues, is improved, that would uniquely confirm the RANTES hypothesis.

[AaHh]

In my thinking, even though a P3 trial to meet Primary is important to the success, the secondaries, if statistically significant is NO reason to shelve this treatment for Covid.

I think they will have to abandon that trial and start a new one with a different primary endpoint and/or more participants. From what I read you can also change the endpoint some time before unblinding but they are not doing that, I don’t know why.